Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Human Vaccines & Immunotherapeutics|December 16, 2020
Long-term effectiveness of the nine-valent human papillomavirus vaccine in Scandinavian women: interim analysis after 8 years of follow-upSusanne K Kjaer, Mari Nygård, Karin Sundström, et al.
The Lancet. Infectious Diseases|September 3, 2023
Safety, efficacy, and immunogenicity of a replication-defective human cytomegalovirus vaccine, V160, in cytomegalovirus-seronegative women: a double-blind, randomised, placebo-controlled, phase 2b trialRituparna Das, Daniel Blázquez-Gamero, David I Bernstein, et al.
Papillomavirus Research (Amsterdam, Netherlands)|July 14, 2020
Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-upSven-Eric Olsson, Jaime Alberto Restrepo, Julio Cesar Reina, et al.
The Journal of Infectious Diseases|September 20, 2019
Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative SubjectsStuart P Adler, Nicole Lewis, Anthony Conlon, et al.
Lancet (London, England)|June 5, 2009
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trialNubia Muñoz, Ricardo Manalastas, Punee Pitisuttithum, et al.
Human Vaccines & Immunotherapeutics|July 19, 2022
Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27-45 yearsIvette Maldonado, Manuel Plata, Mauricio Gonzalez, et al.
Eclinicalmedicine|July 9, 2020
Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countriesSusanne K Kjaer, Mari Nygård, Karin Sundström, et al.
The Lancet. Infectious Diseases|November 15, 2021
Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trialStephen E Goldstone, Anna R Giuliano, Joel M Palefsky, et al.
Pediatrics|January 2, 2021
Three-Year Follow-up of 2-Dose Versus 3-Dose HPV VaccineJacob Bornstein, Surita Roux, Lone Kjeld Petersen, et al.
Pediatrics|September 5, 2023
Ten-Year Follow-up of 9-Valent Human Papillomavirus Vaccine: Immunogenicity, Effectiveness, and SafetyJaime Restrepo, Teobaldo Herrera, Rudiwilai Samakoses, et al.
Pageof 2